CA2881200A1 - Methods of isothermal amplification using blocked primers - Google Patents
Methods of isothermal amplification using blocked primers Download PDFInfo
- Publication number
- CA2881200A1 CA2881200A1 CA2881200A CA2881200A CA2881200A1 CA 2881200 A1 CA2881200 A1 CA 2881200A1 CA 2881200 A CA2881200 A CA 2881200A CA 2881200 A CA2881200 A CA 2881200A CA 2881200 A1 CA2881200 A1 CA 2881200A1
- Authority
- CA
- Canada
- Prior art keywords
- primer
- rnase
- amplification
- flap
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 238000011901 isothermal amplification Methods 0.000 title description 10
- 230000003321 amplification Effects 0.000 claims abstract description 86
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 86
- 108060004795 Methyltransferase Proteins 0.000 claims abstract description 32
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 17
- 230000007017 scission Effects 0.000 claims abstract description 17
- 102100034343 Integrase Human genes 0.000 claims abstract description 15
- 230000001419 dependent effect Effects 0.000 claims abstract description 15
- 108010083644 Ribonucleases Proteins 0.000 claims description 37
- 102000006382 Ribonucleases Human genes 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 32
- 238000003556 assay Methods 0.000 claims description 28
- 150000007523 nucleic acids Chemical group 0.000 claims description 27
- 108091093088 Amplicon Proteins 0.000 claims description 24
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 21
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims description 19
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 18
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 18
- 239000000872 buffer Substances 0.000 claims description 17
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 102000023732 binding proteins Human genes 0.000 claims description 12
- 108091008324 binding proteins Proteins 0.000 claims description 12
- 230000004048 modification Effects 0.000 claims description 10
- 238000012986 modification Methods 0.000 claims description 10
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 9
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 9
- 229940104302 cytosine Drugs 0.000 claims description 9
- 229940029575 guanosine Drugs 0.000 claims description 9
- 108091028664 Ribonucleotide Proteins 0.000 claims description 8
- 239000002336 ribonucleotide Substances 0.000 claims description 8
- 239000001226 triphosphate Substances 0.000 claims description 8
- 235000011178 triphosphate Nutrition 0.000 claims description 8
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 230000000903 blocking effect Effects 0.000 claims description 5
- 238000002844 melting Methods 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 4
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 102100025290 Ribonuclease H1 Human genes 0.000 claims description 2
- 108010052833 ribonuclease HI Proteins 0.000 claims description 2
- 230000035772 mutation Effects 0.000 abstract description 60
- 101150090202 rpoB gene Proteins 0.000 abstract description 26
- 108020001019 DNA Primers Proteins 0.000 abstract description 4
- 239000003155 DNA primer Substances 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 230000001404 mediated effect Effects 0.000 abstract description 3
- 101710203526 Integrase Proteins 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 239000013615 primer Substances 0.000 description 142
- 239000000523 sample Substances 0.000 description 77
- 108020004414 DNA Proteins 0.000 description 60
- 238000006243 chemical reaction Methods 0.000 description 25
- 238000001514 detection method Methods 0.000 description 23
- 108020004707 nucleic acids Proteins 0.000 description 22
- 102000039446 nucleic acids Human genes 0.000 description 22
- 102000004190 Enzymes Human genes 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 16
- 238000009396 hybridization Methods 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 238000013459 approach Methods 0.000 description 13
- 230000035945 sensitivity Effects 0.000 description 13
- 238000012163 sequencing technique Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 201000008827 tuberculosis Diseases 0.000 description 10
- 229920001213 Polysorbate 20 Polymers 0.000 description 9
- 108091006629 SLC13A2 Proteins 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 9
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 9
- 108700028369 Alleles Proteins 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 239000013504 Triton X-100 Substances 0.000 description 7
- 229920004890 Triton X-100 Polymers 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 101150073340 uvrD gene Proteins 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 241000186359 Mycobacterium Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 239000002987 primer (paints) Substances 0.000 description 5
- 229960001225 rifampicin Drugs 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 229960003085 meticillin Drugs 0.000 description 4
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 101150099542 tuf gene Proteins 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 235000012431 wafers Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101100038261 Methanococcus vannielii (strain ATCC 35089 / DSM 1224 / JCM 13029 / OCM 148 / SB) rpo2C gene Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 241001148023 Pyrococcus abyssi Species 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 241000192086 Staphylococcus warneri Species 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 101150085857 rpo2 gene Proteins 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 241000423301 Clostridioides difficile 630 Species 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 108010053229 Lysyl endopeptidase Proteins 0.000 description 2
- 241001467553 Mycobacterium africanum Species 0.000 description 2
- 241001509451 Mycobacterium genavense Species 0.000 description 2
- 241000187919 Mycobacterium microti Species 0.000 description 2
- 241001302239 Mycobacterium tuberculosis complex Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010041925 Staphylococcal infections Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940126575 aminoglycoside Drugs 0.000 description 2
- 230000001745 anti-biotin effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 101150008979 mecA gene Proteins 0.000 description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 150000003376 silicon Chemical class 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 101150089436 tcdB gene Proteins 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000253373 Caldanaerobacter subterraneus subsp. tengcongensis Species 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 101710114816 Gene 41 protein Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 238000007397 LAMP assay Methods 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 241001134667 Mycobacterium celatum Species 0.000 description 1
- 241000187478 Mycobacterium chelonae Species 0.000 description 1
- 241000186365 Mycobacterium fortuitum Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000549435 Pria Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700043532 RpoB Proteins 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- KGTSLTYUUFWZNW-PPJQWWMSSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate pyridine-4-carbohydrazide Chemical compound NNC(=O)c1ccncc1.CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C KGTSLTYUUFWZNW-PPJQWWMSSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910021419 crystalline silicon Inorganic materials 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000015355 drug-resistant tuberculosis Diseases 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 208000036984 extensively drug-resistant tuberculosis Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 101150070420 gyrA gene Proteins 0.000 description 1
- 101150013736 gyrB gene Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 101150012629 parE gene Proteins 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- -1 recombination Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000003201 single nucleotide polymorphism genotyping Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261598648P | 2012-02-14 | 2012-02-14 | |
| US61/598,648 | 2012-02-14 | ||
| PCT/US2013/026202 WO2013123238A1 (en) | 2012-02-14 | 2013-02-14 | Methods of isothermal amplification using blocked primers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2881200A1 true CA2881200A1 (en) | 2013-08-22 |
Family
ID=48984714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2881200A Abandoned CA2881200A1 (en) | 2012-02-14 | 2013-02-14 | Methods of isothermal amplification using blocked primers |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8936921B2 (enExample) |
| EP (1) | EP2814975A4 (enExample) |
| JP (1) | JP6466173B2 (enExample) |
| CA (1) | CA2881200A1 (enExample) |
| HK (1) | HK1205194A1 (enExample) |
| WO (1) | WO2013123238A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014143228A1 (en) * | 2013-03-15 | 2014-09-18 | Integrated Dna Technologies, Inc. | Rnase h-based assays utilizing modified rna monomers |
| US10227641B2 (en) | 2008-04-30 | 2019-03-12 | Integrated Dna Technologies, Inc. | RNase H-based assays utilizing modified RNA monomers |
| US9464319B2 (en) | 2009-03-24 | 2016-10-11 | California Institute Of Technology | Multivolume devices, kits and related methods for quantification of nucleic acids and other analytes |
| US9447461B2 (en) | 2009-03-24 | 2016-09-20 | California Institute Of Technology | Analysis devices, kits, and related methods for digital quantification of nucleic acids and other analytes |
| WO2010111265A1 (en) | 2009-03-24 | 2010-09-30 | University Of Chicago | Slip chip device and methods |
| US10196700B2 (en) | 2009-03-24 | 2019-02-05 | University Of Chicago | Multivolume devices, kits and related methods for quantification and detection of nucleic acids and other analytes |
| WO2013159116A1 (en) | 2012-04-20 | 2013-10-24 | University Of Chicago | Fluidic devices for biospecimen preservation |
| WO2013159117A1 (en) | 2012-04-20 | 2013-10-24 | SlipChip, LLC | Fluidic devices and systems for sample preparation or autonomous analysis |
| US9803237B2 (en) | 2012-04-24 | 2017-10-31 | California Institute Of Technology | Slip-induced compartmentalization |
| US9074248B1 (en) * | 2012-12-18 | 2015-07-07 | Qiagen Gmbh | Primers for helicase dependent amplification and their methods of use |
| WO2017136387A1 (en) * | 2016-02-01 | 2017-08-10 | Integrated Dna Technologies, Inc. | Cleavable primers for isothermal amplification |
| US9617587B1 (en) | 2016-04-04 | 2017-04-11 | Nat Diagnostics, Inc. | Isothermal amplification components and processes |
| US11299777B2 (en) | 2016-04-04 | 2022-04-12 | Nat Diagnostics, Inc. | Isothermal amplification components and processes |
| US11268117B2 (en) | 2016-06-10 | 2022-03-08 | Life Technologies Corporation | Methods and compositions for nucleic acid amplification |
| WO2018180987A1 (ja) * | 2017-03-29 | 2018-10-04 | 東洋紡株式会社 | 核酸の検出方法 |
| CN120210336A (zh) | 2017-10-06 | 2025-06-27 | 10X基因组学有限公司 | Rna模板化连接 |
| CA3079687A1 (en) * | 2017-10-18 | 2019-04-25 | Chiahao TSUI | Selective enrichment of a population of dna in a mixed dna sample through targeted suppression of dna amplification |
| EP4310196A3 (en) | 2017-11-07 | 2024-04-24 | Life Technologies Corporation | Methods and compositions for manipulating nucleic acids |
| US12226745B2 (en) | 2017-11-07 | 2025-02-18 | Life Technologies Corporation | Methods and compositions for manipulating nucleic acids |
| CN109913538A (zh) * | 2018-09-06 | 2019-06-21 | 湖南融健基因生物科技有限公司 | 一种快速检测snp位点的荧光定量试剂盒 |
| EP4403648B1 (en) * | 2019-05-03 | 2025-08-20 | Life Technologies Corporation | Methods and compositions for manipulating nucleic acids |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4876187A (en) | 1985-12-05 | 1989-10-24 | Meiogenics, Inc. | Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences |
| US5011769A (en) | 1985-12-05 | 1991-04-30 | Meiogenics U.S. Limited Partnership | Methods for detecting nucleic acid sequences |
| US5403711A (en) | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
| US5853990A (en) | 1996-07-26 | 1998-12-29 | Edward E. Winger | Real time homogeneous nucleotide assay |
| CN100351393C (zh) | 2001-02-15 | 2007-11-28 | 宝生物工程株式会社 | 核苷酸多态性的检测方法 |
| TW200404889A (en) | 2002-05-31 | 2004-04-01 | Takara Bio Inc | Method of typing gene polymorphisms |
| US7662594B2 (en) * | 2002-09-20 | 2010-02-16 | New England Biolabs, Inc. | Helicase-dependent amplification of RNA |
| AU2003272438B2 (en) | 2002-09-20 | 2009-04-02 | New England Biolabs, Inc. | Helicase dependent amplification of nucleic acids |
| US7824890B2 (en) * | 2005-02-19 | 2010-11-02 | Avacta Group Plc | Isothermal amplification of nucleic acids |
| WO2007120808A2 (en) | 2006-04-14 | 2007-10-25 | Biohelix Corporation | A method of asymmetric helicase-dependent amplification for probe-based detection of targets |
| US8911948B2 (en) | 2008-04-30 | 2014-12-16 | Integrated Dna Technologies, Inc. | RNase H-based assays utilizing modified RNA monomers |
| EP2644707B1 (en) * | 2008-04-30 | 2015-06-03 | Integrated Dna Technologies, Inc. | RNase-H-based assays utilizing modified RNA monomers |
| JP2013507910A (ja) * | 2009-10-13 | 2013-03-07 | シンテッツァ モレキュラー ディテクション イスラエル リミテッド | 核酸試料から標的配列を増幅するための方法および組成物 |
| AU2011204313A1 (en) * | 2010-01-08 | 2012-07-26 | Qiagen Gaithersburg, Inc. | Materials and methods for isothermal nucleic acid amplification |
| CA2799200A1 (en) * | 2010-05-19 | 2011-11-24 | Qiagen Gaithersburg, Inc. | Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids |
-
2013
- 2013-02-14 WO PCT/US2013/026202 patent/WO2013123238A1/en not_active Ceased
- 2013-02-14 CA CA2881200A patent/CA2881200A1/en not_active Abandoned
- 2013-02-14 HK HK15105687.0A patent/HK1205194A1/xx unknown
- 2013-02-14 JP JP2014557780A patent/JP6466173B2/ja active Active
- 2013-02-14 EP EP13748794.8A patent/EP2814975A4/en not_active Withdrawn
- 2013-06-03 US US13/908,827 patent/US8936921B2/en active Active
-
2014
- 2014-12-10 US US14/565,696 patent/US9896723B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20140017730A1 (en) | 2014-01-16 |
| JP2015507931A (ja) | 2015-03-16 |
| US20150176068A1 (en) | 2015-06-25 |
| US8936921B2 (en) | 2015-01-20 |
| JP6466173B2 (ja) | 2019-02-06 |
| WO2013123238A1 (en) | 2013-08-22 |
| HK1205194A1 (en) | 2015-12-11 |
| EP2814975A4 (en) | 2015-12-30 |
| US9896723B2 (en) | 2018-02-20 |
| EP2814975A1 (en) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9896723B2 (en) | Methods of isothermal amplification using blocked primers | |
| US9670531B2 (en) | Dynamic flux nucleic acid sequence amplification | |
| DK2294225T3 (en) | Method for direct amplification from crude nucleic acid samples | |
| AU2015330738B2 (en) | Polymerase chain reaction primers and probes for Mycobacterium tuberculosis | |
| US9115391B2 (en) | Method of detecting a polymorphism at a polymorphism site | |
| EP3910075B1 (en) | Kits for detecting bacterial nucleic acid and diagnosing bacterial vaginosis | |
| Ao et al. | Rapid detection of rpoB gene mutations conferring rifampin resistance in Mycobacterium tuberculosis | |
| JP5756135B2 (ja) | テスト試料中のＣｈｌａｍｙｄｏｐｈｉｌａｐｎｅｕｍｏｎｉａｅの存在を決定するための、組成物、方法およびキット | |
| EP2027293B1 (en) | Method of lysing mycobacterium and amplifying its nucleic acid | |
| JPH09511658A (ja) | 鳥型結核菌複合種の増幅および検出 | |
| US20180044720A1 (en) | Compositions and methods for detecting bv-associated bacterial nucleic acid | |
| JP4744053B2 (ja) | マイコバクテリウム属（Ｍｙｃｏｂａｃｔｅｒｉｕｍ）種の核酸増幅および検出 | |
| US9284603B2 (en) | Target sequence amplification method, polymorphism detection method, and reagents for use in the methods | |
| CN105907878A (zh) | 基于高分辨熔解曲线技术的结核分枝杆菌耐药性基因突变检测 | |
| US9121054B2 (en) | Detection of nucleic acid amplification products in the presence of an internal control sequence on an immunochromatographic strip | |
| EP3387149A1 (en) | Isothermal amplification for the detection of influenza viruses in a sample | |
| JP2009284774A (ja) | 核酸の塩基配列の識別方法 | |
| WO2013132443A1 (en) | Real-time pcr detection of mycobacterium tuberculosis complex | |
| KR20150011699A (ko) | 유전적 변이를 함유하는 핵산 검출 방법 | |
| JP2025155417A (ja) | 結核菌群検出用オリゴヌクレオチド及びその用途 | |
| Whitcombe | 6 Using Scorpion Primers for Genotyping |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20190214 |